Search results for "Methotrexate"

showing 10 items of 111 documents

Incorporation of dynamic boronate links and Ag nanoparticles into PVA hydrogels for pH-Regulated and prolonged release of methotrexate

2021

Abstract In this study, pH-responsive hydrogels based on PVA-boronate crosslinks were prepared via a simple route and used for controlled and targeted delivery of anticancer drug methotrexate. A double network (DN) hydrogel composed of didiol-boronate/PVA complex as the first network and PVA crystallites generated by a freeze-thaw process as the second one was developed. The swelling of PVA-boronate DN hydrogels demonstrated high sensitivity to multiple stimuli including the pH, temperature, and ionic strength of the media thanks to the dynamic boronate links in the first network. Moreover, unlike previously reported hydrogels based on the boronate linkages, the new DN hydrogels preserved t…

inorganic chemicalsChemistrytechnology industry and agricultureCancer therapyPharmaceutical ScienceAg nanoparticlesmacromolecular substances02 engineering and technology021001 nanoscience & nanotechnologycomplex mixtures030226 pharmacology & pharmacyAnticancer drug03 medical and health sciences0302 clinical medicineChemical engineeringProlonged releaseIonic strengthSelf-healing hydrogelsmedicineMethotrexateSwellingmedicine.symptom0210 nano-technologymedicine.drugJournal of Drug Delivery Science and Technology
researchProduct

Oral non-Hodgkin’s lymphoma in a patient with rheumatoid arthritis treated with etanercept and methotrexate

2015

Oral non-Hodgkin’s lymphomas (O-NHLs) are a rare group of diverse lymphoid tissue malignancies and represent less than 5% of the oral cavity malignancies and 2% of all extra-nodal NHLs. Oral-NHLs affect the Waldeyer’s-ring, the salivary glands, the bone of the jaws and the oral mucosa, their clinical appearance is very heterogeneous. Among the risk factors for NHLs are immunosuppression (primary or secondary), autoimmunity and inflammation. O-NHLs share the same risk factors. This case report describes a patient with O-NHL which was possibly linked to the combination of methotrexate and etanercept for the treatment of her rheumatoid arthritis. To our knowledge this is probably among the fir…

medicine.medical_specialtyCase ReportOdontologíaMalignancyEtanerceptimmune system diseaseshemic and lymphatic diseasesmedicineMedical historyOral mucosaGeneral DentistryOral Medicine and Pathologybusiness.industrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludNon-Hodgkin's lymphomaLymphomastomatognathic diseasesmedicine.anatomical_structureRheumatoid arthritisUNESCO::CIENCIAS MÉDICASImmunologyMethotrexatebusinessmedicine.drug
researchProduct

Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis

2013

Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and a significant cause of morbidity and mortality. Usual interstitial pneumonia and nonspecific interstitial pneumonia seem to be the most frequent patterns in RA patients with ILD, although the proportion of patients with usual interstitial pneumonia is higher than among patients with other systemic rheumatic autoimmune diseases. RA patients with ILD most frequently present with chronic symptoms of cough and dyspnea when climbing stairs or walking uphill. A physical examination may reveal inhalatory crackles and a pulmonary function test demonstrates restrictive physiology, often with re…

medicine.medical_specialtyImmunologyArthritisLung biopsyGastroenterologyPulmonary function testingArthritis RheumatoidAntibodies Monoclonal Murine-DerivedPatient Education as TopicUsual interstitial pneumoniaInternal medicinemedicineHumansImmunology and AllergyAntibodies BlockingPneumonitisLeflunomideClinical Trials as TopicTumor Necrosis Factor-alphabusiness.industryInterstitial lung diseaseIsoxazolesmedicine.diseaserespiratory tract diseasesMethotrexateAntirheumatic AgentsRheumatoid arthritisImmunologyLung Diseases InterstitialRituximabbusinessLeflunomidemedicine.drugExpert Review of Clinical Immunology
researchProduct

Comparing medical treatments for Crohn’s disease

2013

The drugs available for inflammatory bowel disease are aminosalicylates, antibiotics, steroids, immunosuppressors and biologics. The effectiveness of these drugs has been evaluated in many randomized clinical trials, mainly versus placebo. Few studies have been conducted comparing the different drugs among themselves, owing to the methodological problems raised by comparative trials, such as sample size and blindness. This review focuses mainly on the randomized clinical trials that have compared different treatments. Of course comparisons are mainly between drugs used in a particular setting (mild, moderate and severe disease). However, on many occasions there is no homogeneity in these cl…

medicine.medical_specialtyPathologymedicine.drug_classAntibioticsAlternative medicineSevere diseasePlaceboInflammatory bowel diseaselaw.inventionBiological FactorsCrohn DiseaseRandomized controlled trialAdrenal Cortex HormoneslawInternal medicineAzathioprineIntestinal FistulaSecondary PreventionmedicineHumansBudesonideRandomized Controlled Trials as TopicCrohn's diseasebusiness.industryProbioticsHealth Policymedicine.diseaseAnti-Bacterial AgentsAminosalicylic AcidsMethotrexateSample size determinationbusinessJournal of Comparative Effectiveness Research
researchProduct

Management options for low-dose methotrexate-induced oral ulcers : a systematic review

2019

Background Oral ulcers caused by methotrexate (MTX) at low doses are a known side effect of this drug. Although increasingly more patients are medicated with MTX, these painful ulcers, without traumatic origin and resistant to any type of treatment, are not usually identified by health professionals as a side effect of the medication. Material and Methods In the absence of a consensus protocol for the effective treatment of oral lesions produced by MTX, the objective of this article was to review and analyse the information from articles related to oral ulcers produced by low-dose MTX and to record the clinical management performed and the MTX dose given to the patient. Data sources - Medli…

medicine.medical_specialtySide effectDatabases FactualPsychological interventionMEDLINEAdministration OralReviewCochrane Library03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansGeneral DentistryOral UlcerProtocol (science)Oral Medicine and Pathologybusiness.industry030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Systematic reviewMethotrexateTreatment OutcomeOtorhinolaryngologySample size determinationUNESCO::CIENCIAS MÉDICASSurgeryBradford Hill criteriabusiness
researchProduct

Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis.

2012

Ocular inflammatory disorders constitute a sight-threatening group of diseases that might be managed according to their severity. Their treatment guidelines experience constant changes with new agents that improve the results obtained with former drugs. Nowadays we can make use of a five step protocol in which topical, periocular and systemic corticosteroids remain as the main therapy for non-infectious uveitis. In addition, immunosuppresive drugs can be added in order to enhance the anti-inflammatory effects and to play the role of corticosteroid-sparing agents. These can be organized in four other steps: cyclosporine and methotrexate in a second one; azathioprine, mycophenolate and tacrol…

medicine.medical_specialtyTreatment protocolCyclophosphamideAdministration TopicalImmunologyAnti-Inflammatory AgentsAzathioprineUveitisInfectious uveitisAdrenal Cortex HormonesmedicineImmunology and AllergyAnimalsHumansIntensive care medicinePharmacologyChlorambucilbusiness.industryTumor Necrosis Factor-alphaGeneral Medicinemedicine.diseaseTacrolimusSurgeryInjections IntravenousPractice Guidelines as TopicMethotrexateImmunotherapybusinessUveitisAlgorithmsImmunosuppressive Agentsmedicine.drugInflammationallergy drug targets
researchProduct

Treatment of early childhood medulloblastoma by postoperative chemotherapy alone.

2005

The prognosis for young children with medulloblastoma is poor, and survivors are at high risk for cognitive deficits. We conducted a trial of the treatment of this brain tumor by intensive postoperative chemotherapy alone.After surgery, children received three cycles of intravenous chemotherapy (cyclophosphamide, vincristine, methotrexate, carboplatin, and etoposide) and intraventricular methotrexate. Treatment was terminated if a complete remission was achieved. Leukoencephalopathy and cognitive deficits were evaluated.Forty-three children were treated according to protocol. In children who had complete resection (17 patients), residual tumor (14), and macroscopic metastases (12), the five…

medicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentIntelligenceBrain tumorNeuropsychological TestsCarboplatinchemistry.chemical_compoundAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansCerebellar NeoplasmsCyclophosphamideEtoposideEtoposideProportional Hazards ModelsMedulloblastomaPostoperative CareChemotherapyAnalysis of Variancebusiness.industryDesmoplastic medulloblastomaRemission InductionInfantGeneral Medicinemedicine.diseaseSurvival AnalysisCarboplatinSurgeryMethotrexatechemistryChemotherapy AdjuvantVincristineChild PreschoolNeoplasm Recurrence Localbusinessmedicine.drugFollow-Up StudiesMedulloblastomaThe New England journal of medicine
researchProduct

Immunoadsorption with tryptophan columns: A therapeutic option for the treatment of rheumatoid arthritis with septic complications

2009

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease affecting multiple organs and tissues. Although there is a wide range of therapeutic applications, the coexistence of severe side effects and contraindications outlines the necessity of new therapeutic options in the treatment of severe RA. We report on the case of a 71-year-old patient with successful treatment of a complicated RA with tryptophan immunoadsorption combined with low-dose steroids. Bacterial spondylitis developed in this patient during long-term treatment with infliximab and methotrexate. Weekly immunoadsorption sessions with tryptophan columns resulted in continuous suppression of RA activity over a perio…

medicine.medical_specialtyVisual analogue scaleGastroenterologyArthritis RheumatoidRefractorySepsisInternal medicineHumansMedicineImmunoadsorptionSpondylitisImmunosorbent TechniquesAgedAutoimmune diseasebusiness.industryTryptophanBacterial InfectionsHematologyGeneral Medicinemedicine.diseaseInfliximabSurgeryTreatment OutcomeRheumatoid arthritisSteroidsMethotrexatebusinessSpondylitismedicine.drugJournal of Clinical Apheresis
researchProduct

FRI0044 Non-steroidal anti-inflammatory drugs are more beneficial than anti-tnfα drugs on the radiographic damage in arthritis: a study in adjuvant i…

2017

Background The management of the chronic inflammatory rheumatisms has dramatically evolved in the last decade with a concept of “treat to target”. The theory of a window of opportunity with more beneficial effects of an early intensive treatment is supported by several evidences. The positive impact of an early treatment with a TNFα blocker is expected but the place and the interest of non-steroidal anti-inflammatory treatments (NSAIDs) and glucocorticoids is not clear. Objectives The aim of this study was to evaluate the radiological outcomes after an early treatment during 21 days by Etanercept, or Naproxene, or Celecoxib, or Prednisone, or Diclofenac or Methotrexate in adjuvant induced a…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentArthritisSystemic inflammationmedicine.diseaseGastroenterologyEtanerceptDiclofenacPrednisoneInternal medicinemedicineCelecoxibMethotrexatemedicine.symptombusinessAdjuvantmedicine.drugPoster Presentations
researchProduct

AB0266 METHOTREXATE AND CARDIOVASCULAR RISK IN RHEUMATIC DISEASES:A COMPREHENSIVE REVIEW

2021

Background:The management of inflammatory rheumatic disease has evolved in the last decade with the importance of the management of comorbidities. Methotrexate is the cornerstone of inflammatory rheumatic disease management, but its cardiovascular effects are still poorly understoodObjectives:To assess the cardiovascular impact of methotrexate in inflammatory rheumatic disease.Methods:A systematic review of the literature, following the prisma recommandations, was performed on the PubMed and Embase databases with the following keywords: (“Methotrexate”) AND (“cardiovascular”). We included papers written in English and including patients older than 18 years.Results:570 references were identi…

medicine.medical_specialtyeducation.field_of_studymedicine.diagnostic_testbusiness.industryImmunologyPopulationDiseasemedicine.diseaseSystemic inflammationGeneral Biochemistry Genetics and Molecular BiologyPsoriatic arthritisRheumatologyRheumatoid arthritisInternal medicinemedicineImmunology and AllergyMethotrexateMyocardial infarctionmedicine.symptomLipid profileeducationbusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct